SEC Form 6-K Summary
Registrant: NLS Pharmaceutics Ltd. (the source metadata identifies the company as Newcelx Ltd.; the filing itself names NLS Pharmaceutics Ltd.)
Reporting period: May 2021, filed May 14, 2021. The filing reports a restatement of financial statement classifications for the years ended December 31, 2019 and 2018.
Business Context and Filing Purpose
During the audit of the 2020 financial statements, the company identified an error in the presentation of intellectual property expenses in previously filed Form F-1 financial statements. The expenses were classified as research and development rather than general and administrative expenses.
The Form 6-K was furnished to correct the classification error. The company files annual reports on Form 20-F.
Financial Impact of Restatement
| Year ended December 31 | Metric | Previously reported | Adjustment | As restated |
|---|---|---|---|---|
| 2019 | Research and development expenses | $1,702,117 | $(804,329) | $897,788 |
| 2019 | General and administrative expenses | $2,494,922 | $804,329 | $3,299,251 |
| 2019 | Total operating expenses | $4,197,039 | $0 | $4,197,039 |
| 2018 | Research and development expenses | $1,437,202 | $(728,747) | $708,455 |
| 2018 | General and administrative expenses | $2,011,659 | $728,747 | $2,740,406 |
| 2018 | Total operating expenses | $3,448,861 | $0 | $3,448,861 |
Material Changes and Other Items
- The restatement changed the allocation between research and development and general and administrative expenses.
- Total operating expenses, net loss, loss per share, and balance sheet amounts were not affected.
- The filing does not provide revenue, cash flow, margin, debt, liquidity, guidance, or outlook figures.
Risks and Contingencies
The filing describes a financial statement classification error identified during the 2020 audit. It does not disclose additional contingencies, regulatory matters, or operational risks in the provided text.
Key Facts for Investor Verification
- Verify the registrant identity, because the provided metadata says Newcelx Ltd., while the filing names NLS Pharmaceutics Ltd.
- Confirm that the 2018 and 2019 restatements affect expense classification only and do not change total operating expenses, net loss, loss per share, or the balance sheet.
- Review the company’s subsequently filed Form 20-F and other reports for any additional audit adjustments or financial statement amendments.
- Assess whether the reclassification affects internal analysis of research spending versus corporate and administrative costs.